Vaccine Info

SurVaxM Cancer Vaccine

Authored by
Last reviewed
June 16, 2023
Fact checked by
Robert Carlson, MD

SurVaxM Vaccine Description

SurVaxM is a peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastoma, and many other cancers.

It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumor growth and recurrence.

While vaccines are typically thought of as ways to prevent diseases, vaccines can also be used in a therapeutic mode (e.g., to treat cancer).

SurVaxM demonstrated safety and tolerability in a Phase I study in patients with recurrent or progressive malignant glioma (brain tumors).

SurVaxM has now entered a Phase II clinical trial in adults with newly diagnosed glioblastoma. at leading cancer centers: Roswell Park Cancer Institute, Cleveland Clinic, and Dana-Farber Cancer Institute.

MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012.

SurVaxM Vaccine Indication

Although SurVaxM was first tested in brain cancer, survivin is present in most cancers, including multiple myeloma, melanoma, ovarian, renal, lymphoma, prostate, and breast cancers.

SurVaxM is an immunostimulant targeting survivin, a molecule that is present in many cancers.

SurVaxM Vaccine Dosage

SurVaxM is delivered through a subcutaneous injection.

SurVaxM Vaccine News

May 30, 2020 - MimiVax LLC announced a clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma, and many other cancers.

May 29, 2019 - MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics for cancer and autoimmune diseases, announced upcoming presentations at leading scientific and industry events.

SurVaxM Vaccine Clinical Trial

Clinical Trial NCT02455557:  SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

  • This phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma.
  • Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to kill tumor cells that express survivin.
  • Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
  • It is not yet known whether temozolomide is more effective with or without vaccine therapy in treating glioblastoma.

A Phase 2 study now open at the Cleveland Clinic, Cleveland OH. The goal is to establish the safety and tolerability of the drug combination and assess the clinical activity of SurVaxM with pembrolizumab in patients with recurrent glioblastoma. Patients at a first recurrence of glioblastoma who have failed prior chemotherapy and radiation are eligible. The results of this study will be used to further clinical development of this combination in glioblastoma.

Clinical Trials

No clinical trials found